Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review - Takeaways - MDSpire

Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review

  • By

  • M. M.B. Horstink

  • W. J.R. Rietdijk

  • D. R. Geel

  • P. E. Deetman

  • H. Endeman

  • B. C.P. Koch

  • C. A. den Uil

  • December 2, 2025

  • 0 min

Share

  • 1

    Acute kidney injury (AKI) affects 20-75% of critically ill patients, complicating antibiotic dosing in the ICU.

  • 2

    Beta-lactam antibiotics are commonly used in the ICU but require dose adjustments based on kidney function, which is often unreliable.

  • 3

    Initial dose reductions of beta-lactam antibiotics may be unnecessary in patients with transient AKI, as renal function often improves within 48 hours.

  • 4

    The review aims to systematically evaluate the evidence on beta-lactam dosing adjustments and their impact on clinical outcomes in AKI patients.

  • 5

    Current literature suggests postponing dose reductions for 48 hours to optimize treatment while minimizing toxicity risks.

Original Source(s)

Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review

  • by M. M.B. Horstink, W. J.R. Rietdijk, D. R. Geel, P. E. Deetman, H. Endeman, B. C.P. Koch, C. A. den Uil

  • December 2, 2025

Related Content

Assessing the Need for Referrals in Febrile Pediatric Patients in Resource-Limited Communities of South and Southeast Asia

Correlation of Shock-Lactate Index with 28-Day Mortality in Patients Experiencing Sepsis-Related AKI: An Analysis Using the MIMIC-IV Database

Association between baseline-stratified trajectory subgroups of serum albumin and outcomes in critically ill patients with early sepsis-associated acute kidney injury: a retrospective study